DE602004027039D1 - Cytokinpolypeptidvarianten - Google Patents

Cytokinpolypeptidvarianten

Info

Publication number
DE602004027039D1
DE602004027039D1 DE602004027039T DE602004027039T DE602004027039D1 DE 602004027039 D1 DE602004027039 D1 DE 602004027039D1 DE 602004027039 T DE602004027039 T DE 602004027039T DE 602004027039 T DE602004027039 T DE 602004027039T DE 602004027039 D1 DE602004027039 D1 DE 602004027039D1
Authority
DE
Germany
Prior art keywords
amino acid
ligand
native
terminal
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004027039T
Other languages
English (en)
Inventor
Jon Sayers
Peter Artymuik
Richard Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asterion Ltd
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Publication of DE602004027039D1 publication Critical patent/DE602004027039D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Error Detection And Correction (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
DE602004027039T 2003-06-28 2004-06-28 Cytokinpolypeptidvarianten Expired - Fee Related DE602004027039D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315182.6A GB0315182D0 (en) 2003-06-28 2003-06-28 Cytokine variant polypeptides
PCT/GB2004/002827 WO2005003165A2 (en) 2003-06-28 2004-06-28 Cytokine variant polypeptides

Publications (1)

Publication Number Publication Date
DE602004027039D1 true DE602004027039D1 (de) 2010-06-17

Family

ID=27676290

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027039T Expired - Fee Related DE602004027039D1 (de) 2003-06-28 2004-06-28 Cytokinpolypeptidvarianten

Country Status (8)

Country Link
US (1) US20070264234A1 (de)
EP (1) EP1639002B1 (de)
JP (1) JP2008504001A (de)
AT (1) ATE466880T1 (de)
CA (1) CA2568859A1 (de)
DE (1) DE602004027039D1 (de)
GB (1) GB0315182D0 (de)
WO (1) WO2005003165A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266184A1 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
US9885050B2 (en) * 2007-11-08 2018-02-06 The University Of Chicago Molecular affinity clamp technology and uses thereof
CA2730721C (en) * 2008-08-25 2016-08-09 Viromed Co., Ltd. Biopolymer conjugates comprising an interleukin-11 analog
KR101853405B1 (ko) 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
DK2859015T3 (en) * 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
WO2019165017A1 (en) 2018-02-23 2019-08-29 The University Of Chicago Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
CN1195776C (zh) * 1997-09-08 2005-04-06 新陈代谢药物有限公司 肥胖症的治疗
AU6246599A (en) * 1998-09-25 2000-04-17 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
AU2003256566A1 (en) * 2002-07-16 2004-02-02 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers

Also Published As

Publication number Publication date
ATE466880T1 (de) 2010-05-15
GB0315182D0 (en) 2003-08-06
US20070264234A1 (en) 2007-11-15
EP1639002A2 (de) 2006-03-29
CA2568859A1 (en) 2005-01-13
JP2008504001A (ja) 2008-02-14
EP1639002B1 (de) 2010-05-05
WO2005003165A2 (en) 2005-01-13
WO2005003165A3 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
EP2360180A3 (de) Motive der bauchspeicheldrüsen-polypeptid familie, polypeptide und methoden und verwendung derselben
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2006001023A3 (en) Chimeric proteins and uses thereof
EP2298331A3 (de) Verwendung von Transthyretinpeptid-/-proteinfusionen zur Erhöhung der Serumshalbwertszeit von pharmakologisch aktiven Peptiden/Proteinen
EP1432433A4 (de) Antagonisten
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
EP2031063A3 (de) Modulatoren von Duftrezeptoren
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
GEP20115333B (en) Antagonist antibodies directed against calcitonin generelated peptide and using same
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
EP2949658A3 (de) Spezifisch an HGF-Rezeptor (cMet) bindende Peptide und deren Verwendung
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
RS50966B (sr) Agonisti pyy i njihova upotreba
WO2005087811A3 (en) Estrogen receptors and methods of use
EP2343318A3 (de) Antikörper die an ein C-terminales Fragment des Apolipoproteins E binden
EA200600477A1 (ru) Пептиды и соединения, которые связываются с рецептором
DE69834643D1 (de) Adipozyten-spezifische protein homologe
ITRM990803A0 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DE602004027039D1 (de) Cytokinpolypeptidvarianten
ATE323763T1 (de) Dna & protein bindende miniatur proteine
WO2006049983A3 (en) Peptide yy modified transferrin fusion proteins
WO2005044845A3 (en) Protein binding miniature proteins
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee